BackJazz Pharmaceuticals plc Overview
Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc Target Price

Analysts' average 12-month price target for Jazz Pharmaceuticals plc is $280.

Get informed when a big investor buys or sells

+ Follow

Share Price

$240.07

Average Target Price

$284.4818.5% upside

29 analysts in the last 4 months

High: $322 | Low: $229

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-28RBC CapitalLeonid Timashev$29924.5% upsideOpen
2026-08-26RBC CapitalLeonid Timashev$27715.4% upsideOpen
2026-08-26Truist FinancialGregory Renza$28117% upsideOpen
2026-08-26Morgan Stanley$32234.1% upsideOpen
2026-08-26Needham$31029.1% upsideOpen
2026-08-26Canaccord GenuityGary Newman$30025% upsideOpen
2026-08-26Deutsche BankDavid Hoang$30025% upsideOpen
2026-08-11Morgan Stanley$28317.9% upsideOpen
2026-08-04Deutsche Bank$28719.5% upsideOpen
2026-08-04Truist Financial$30025% upsideOpen
2026-08-04Morgan Stanley$28016.6% upsideOpen
2026-08-04Truist Financial$26410% upsideOpen
2026-08-04NeedhamAmi Fadia$29221.6% upsideOpen
2026-08-04UBS$31531.2% upsideOpen
2026-08-04Wells Fargo$30025% upsideOpen
2026-08-04Stifel Nicolaus$27514.5% upsideOpen
2026-08-04Piper Sandler$31029.1% upsideOpen
2026-08-04Robert W. Baird$28016.6% upsideOpen
2026-08-04Barclays$27012.5% upsideOpen
2026-07-16Canaccord GenuityGary Nachman$29020.8% upsideOpen
2026-07-14Wells Fargo$28518.7% upsideOpen
2026-07-14Barclays$2608.3% upsideOpen
2026-07-09Deutsche Bank$27012.5% upsideOpen
2026-07-07Truist FinancialGregory Renza$2545.8% upsideOpen
2026-06-09Truist FinancialGregory Renza$2566.6% upsideOpen
2026-05-27Barclays$2535.4% upsideOpen
2026-05-22Piper Sandler$30125.4% upsideOpen
2026-05-21Bernstein$2294.6% downsideOpen
2026-05-19UBSAshwani Verma$30727.9% upsideOpen
2026-05-07Morgan StanleySean Laaman$2452.1% upsideOpen
2026-05-06Raymond JamesTiago Fauth$2390.4% downsideOpen
2026-05-06Robert W. Baird$2525% upsideOpen
2026-05-06BarclaysEtzer Darout$2342.5% downsideOpen
2026-04-20BarclaysEtzer Darout$2256.3% downsideOpen
2026-04-10Raymond James$2275.4% downsideOpen
2026-03-09BarclaysEtzer Darout$2246.7% downsideOpen
2026-01-12NeedhamAmi Fadia$2352.1% downsideOpen
2026-01-08Morgan StanleySean Laaman$2256.3% downsideOpen
2025-12-10Piper SandlerDavid Amsellem$2198.8% downsideOpen
2025-11-24UBSAshwani Verma$18821.7% downsideOpen
2025-11-17RBC Capital$19419.2% downsideOpen
2025-11-17Morgan StanleySean Laaman$20514.6% downsideOpen
2025-10-24Morgan Stanley$18323.8% downsideOpen
2025-10-22Wells Fargo$17029.2% downsideOpen
2025-10-20Morgan Stanley$18025% downsideOpen
2025-08-28Truist FinancialJoon Lee$20514.6% downsideOpen
2025-08-28RBC CapitalGregory Renza$15137.1% downsideOpen
2025-08-28Morgan Stanley$16332.1% downsideOpen
2025-07-15Deutsche BankDavid Hoang$15236.7% downsideOpen
2025-03-06Truist Financial$2304.2% downsideOpen

Jazz Pharmaceuticals plc (JAZZ) FAQ

Jazz Pharmaceuticals plc posts a target price of $280. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $280 for JAZZ means covering analysts, on average, see the stock 18.5% upside of $240.07 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for JAZZ's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Jazz Pharmaceuticals plc's other metric pages and overview cover the third.

Judging Jazz Pharmaceuticals plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $280 here, then scan peer and history charts to see if the gap is persistent.